Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.83 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ME3 | Q16798 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049597 | 0.92 | EPHX2 (0.90) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL2753089 | 0.92 | EPHX2 (0.96) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL8233566 | 0.91 | EPHX2 (0.71) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL16545220 | 0.91 | EPHX2 (0.71) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL30590228 | 0.91 | EPHX2 (0.71) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL5051924 | 0.91 | EPHX2 (1.00) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL3397254 | 0.91 | EPHX2 (1.00) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL5047929 | 0.91 | EPHX2 (0.93) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL9776408 | 0.89 | EPHX2 (0.73) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL4693545 | 0.88 | EPHX2 (0.71) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | claimed |
| US-20240383863-A1 | PREPARATION METHOD FOR PYRIMIDINE-2-AMINE | INSTITUTE FOR BASIC SCIENCE (KR) | 2024-11-21 | — | — | US | disclosed |
| WO-2023043292-A1 | PREPARATION METHOD FOR PYRIMIDINE-2-AMINE | 기초과학연구원 | 2023-03-23 | — | — | WO | disclosed |
| US-20190077824-A1 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS | LEWIS AND CLARK PHARMACEUTICALS INC | 2019-03-14 | — | — | US | disclosed |
| US-20190077824-A1 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS | LEWIS AND CLARK PHARMACEUTICALS INC | 2019-03-14 | — | — | US | disclosed |
| US-9822141-B2 | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists | LEWIS AND CLARK PHARMACEUTICALS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822141-B2 | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists | LEWIS AND CLARK PHARMACEUTICALS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822141-B2 | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists | LEWIS AND CLARK PHARMACEUTICALS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170283452-A9 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS | LEWIS AND CLARK PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283452-A9 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS | LEWIS AND CLARK PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9067963-B2 | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists | Lewis and Clark Pharmaceuticals, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2879683-A1 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS | Lewis and Clark Pharmaceuticals, Inc. (US) | 2015-06-10 | — | — | EP | disclosed |
| CN-104582709-A | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists | LEWIS AND CLARK PHARMACEUTICALS INC | 2015-04-29 | — | — | CN | disclosed |
| US-20140037538-A1 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS | LEWIS AND CLARK PHARMACEUTICALS, INC. | 2014-02-06 | — | — | US | disclosed |
| US-20140037538-A1 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS | LEWIS AND CLARK PHARMACEUTICALS, INC. | 2014-02-06 | — | — | US | disclosed |
| US-20140037538-A1 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS | LEWIS AND CLARK PHARMACEUTICALS, INC. | 2014-02-06 | — | — | US | disclosed |
| WO-2014022577-A1 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS | LEWIS AND CLARK PHARMACEUTICALS, INC. (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383863-A1 | PREPARATION METHOD FOR PYRIMIDINE-2-AMINE | NUDT1, UMPS, DPYD | EPHX2 1084/4885SIGMAR1 4256/4885MEN1 1037/4885 |
| US-20170283452-A9 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS | ADORA2A, ADORA3, ADORA1 | EPHX2 969/4885SIGMAR1 757/4885MEN1 3658/4885 |
| US-20140037538-A1 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS | ADORA2A, ADORA3, ADORA1 | EPHX2 969/4885SIGMAR1 757/4885MEN1 3658/4885 |
| US-20190077824-A1 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS | ADORA2A, ADORA3, ADORA1 | EPHX2 969/4885SIGMAR1 757/4885MEN1 3658/4885 |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | EPHX2 3812/4885SIGMAR1 468/4885MEN1 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.